Targeting CD33 for acute myeloid leukemia therapy
J Liu, J Tong, H Yang - BMC cancer, 2022 - Springer
Background The aim of this study was to analyze the level of CD33 expression in patients
with newly diagnosed AML and determine its correlation with clinical characteristics …
with newly diagnosed AML and determine its correlation with clinical characteristics …
The role of CD33 as therapeutic target in acute myeloid leukemia
RB Walter - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML)
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives
WR Sperr, S Florian, AW Hauswirth… - Leukemia & …, 2005 - Taylor & Francis
CD33 is a myeloid cell surface antigen that is expressed on blast cells in acute myeloid
leukemia (AML) in a majority of all patients regardless of age or subtype of disease. The …
leukemia (AML) in a majority of all patients regardless of age or subtype of disease. The …
Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia
ÅR Derolf, E Björklund, J Mazur, M Björkholm… - Leukemia & …, 2008 - Taylor & Francis
Expression patterns of CD33 and CD15 in normal/reactive bone marrow (n= 13) and in
leukemic blasts from patients with acute myeloid leukemia (n= 129) were determined using …
leukemic blasts from patients with acute myeloid leukemia (n= 129) were determined using …
[HTML][HTML] Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia
AA Laing, CJ Harrison, BES Gibson… - Experimental hematology, 2017 - Elsevier
Highlights•This review provides a summary of the genetic, biological, and cellular
differences between adult and childhood acute myeloid leukemia (AML).•The role of …
differences between adult and childhood acute myeloid leukemia (AML).•The role of …
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …
The past and future of CD33 as therapeutic target in acute myeloid leukemia
GS Laszlo, EH Estey, RB Walter - Blood reviews, 2014 - Elsevier
CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …
CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes
W Zheng, LJ Medeiros, Y Hu, L Powers… - … Myeloma and Leukemia, 2013 - Elsevier
Background We assessed for CD30 expression in patients with acute myeloid leukemia
(AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti …
(AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti …
Prognostic value of CD11b expression level for acute myeloid leukemia patients: a meta-analysis
S Xu, X Li, J Zhang, J Chen - PLoS One, 2015 - journals.plos.org
Background Study results on the prognostic value of CD11b for acute myeloid leukemia
(AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the …
(AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the …
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia
CD Godwin, GS Laszlo, BL Wood, CE Correnti… - Leukemia, 2020 - nature.com
There is long-standing interest in therapies targeting fulllength CD33 (CD33FL) for acute
myeloid leukemia (AML)[1–3]. Longer survival with gemtuzumab ozogamicin (GO) in some …
myeloid leukemia (AML)[1–3]. Longer survival with gemtuzumab ozogamicin (GO) in some …